Inhibition of NF-κB-induced inflammatory responses by angiotensin II antagonists in aged rat kidney

Experimental Gerontology

Volumn 46, Issue 7, 2011, Pages 542-548

  Kim, Ji Min ^a   Heo, Hyoung Sam ^a   Choi, Yeon Ja ^a   Ye, Byeong Hyeok ^a   Mi Ha, Young ^a   Seo, Arnold Young ^b   Yu, Byung Pal ^c   Leeuwenburgh, Christiaan ^b   Chung, Hae Young ^a   Carter, Christy S ^b  

^a Pusan National University   (South Korea)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Aging; Inflammation; Oxidative stress; Renin angiotensin system

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 2; ENALAPRIL; GLUTATHIONE; GLUTATHIONE DISULFIDE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; LOSARTAN; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE 1; PEROXYNITRITE; PLACEBO; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR RELA; VASCULAR CELL ADHESION MOLECULE 1;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BROWN NORWAY RAT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; FISCHER 344 RAT; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; INHIBITION KINETICS; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION; WESTERN BLOTTING;

AGING; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ENALAPRIL; GENE EXPRESSION; KIDNEY; LOSARTAN; MALE; MAP KINASE SIGNALING SYSTEM; NEPHRITIS; NF-KAPPA B; OXIDATIVE STRESS; PHOSPHORYLATION; RANDOM ALLOCATION; RATS; RATS, INBRED BN; RATS, INBRED F344; TRANSCRIPTION FACTOR RELA;

RATTUS;

EID: 79956320165     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2011.02.011     Document Type: Article

References (40)

1. Anderson S., Meyer T.W., Rennke H.G., Brenner B.M. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 1996, 612-619.
2. Basso N., Paglia N., Stella I., de Cavanagh E.M., Ferder L., Arnaiz M., Inserra F. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul. Pept. 2005, 247-252.
3. Carey R.M. Angiotensin receptors and aging. Hypertension 2007, 33-34.
4. Carter C.S., Cesari M., Ambrosius W.T., Hu N., Diz D., Oden S., Sonntag W.E., Pahor M. Angiotensin-converting enzyme inhibition, body composition, and physical performance in aged rats. J. Gerontol. A Biol. Sci. Med. Sci. 2004, 59:416-423.
5. Carter, C.S., Giovannini, S., Seo, D.O., Dupree, J., Morgan, D., Chung, H.Y., Lees, H., Daniels, M., Hubbard, G.B., Lee, S., Ikeno, Y., Foster, T.C., Buford, T.W., Marzetti, E., 2011. Differential effects of enalapril and losartan on body composition and indices of muscle quality in aged male Fischer 344 x Brown Norway rats. Age (Dordr.), ahead of print.
6. Cassis P., Conti S., Remuzzi G., Benigni A. Angiotensin receptors as determinants of life span. Pflügers Arch. Eur. J. Physiol. 2010, 459:325-332.
7. Cheng Z.J., Vapaatalo H., Mervaala E. Angiotensin II and vascular inflammation. Med. Sci. Monit. 2005, 194-205.
8. Chung H.Y., Kim H.J., Kim K.W., Choi J.S., Yu B.P. Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. Microsc. Res. Tech. 2002, 59(2002):264-272.
9. Chung H.Y., Cesari M., Anton S., Marzetti E., Giovannini S., Seo A.Y., Carter C., Yu B.P., Leeuwenburgh C. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res. Rev. 2008, 8:18-30.
10. Ciechanowicz A. Molecular mechanisms of nephro-protective action of enalapril in experimental chronic renal failure. Ann. Acad. Med. Stetin. 1999, 1-93.
11. Cunha V., Tham D.M., Martin-McNulty B., Deng G., Ho J.J., Wilson D.W., Rutledge J.C., Vergona R., Sullivan M.E., Wang Y.X. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 2005, 9-17.
12. da Silva Lemos M., Nardoni Gonçalves Braga A., Roberto da Silva J., Augusto Souza Dos Santos R. Altered cardiovascular responses to chronic angiotensin II infusion in aged rats. Regul. Pept. 2005, 67-73.
13. de Grey A.D. The case for prioritizing research on late-onset life-extension interventions in mammals. Rejuvenation Res. 2007, 10:257-259.
14. Feinman R., Siegel D., Berenson J. Regulation of NF-kB in multiple myeloma: therapeutic implications. Clin. Adv. Hematol. Oncol. H&O 2004, 2:162.
15. Griendling K.K., Minieri C.A., Ollerenshaw Z.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 1994, 1141-1148.
16. κB signaling module: temporal control and selective gene activation. Science 2002, 1241-1245.
17. Inserra F., Romano L., Ercole L., de Cavanagh E.M., Ferder L. Cardiovascular changes by long-term inhibition of the renin-angiotensin system in aging. Hypertension 1995, 437-442.
18. Inserra F., Basso N., Ferder M., Userpater M., Stella I., Paglia N., Inserra P., Tenembaum D., Ferder L. Changes seen in the aging kidney and the effect of blocking the renin-angiotensin system. Ther. Adv. Cardiovasc. Dis. 2009, 341-346.
19. Ishida S. Lifestyle-related diseases and anti-aging ophthalmology: suppression of retinal and choroidal pathologies by inhibiting renin-angiotensin system and inflammation. Nippon Ganka Gakkai Zasshi 2009, 403-422.
20. Kang Y.M., Ma Y., Elks C., Zheng J.P., Yang Z.M. Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-kappaB. Cardiovasc. Res. 2008, 671-678. Francis J.
21. Kosugi R., Shioi T., Watanabe-Maeda K., Yoshida Y., Takahashi K., Machida Y., Izumi T. Angiotensin II receptor antagonist attenuates expression of aging markers in diabetic mouse heart. Circ. J. 2006, 482-488.
22. Laursen J., Rajagopalan S., Galis Z., Tarpey M., Freeman B., Harrison D. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997, 588-593.
23. Li C., Sun B.K., Lim S.W., Song J.C., Kang S.W., Kim Y.S., Kang D.H., Cha J.H., Kim J., Yang C.W. Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporin induced hepatic pathology. Transplantation 2005, 1522-1529.
24. Moningka, N.C., Sasser, J.M., Croker, B., Carter, C., Baylis, C., 2011. Protection against age-dependent renal injury in the F344xBrown Norway male rat is associated with maintained nitric oxide synthase. Mech. Ageing Dev. 132 (1-2), 1-7.
25. Olshansky S.J., Goldman D.P., Zheng Y., Rowe J.W. Aging in America in the twenty-first century: demographic forecasts from the MacArthur Foundation Research Network on an Aging Society. Milbank Q. 2009, 87:842-862.
26. Ordaz-Medina S.M., González-Plascencia J., Martín del Campo F., Rojas-Campos E., Montañez-Fernández J.L., Espinoza-Gómez F., Cueto-Manzano A.M. Is systemic inflammation of hemodialysis patients improved with the use of enalapril?. ASAIO J. 2010, 37-41.
27. Rae M.J., Butler R.N., Campisi J., de Grey A.D., Finch C.E., Gough M., Martin G.M., Vijg J., Perrott K.M., Logan B.J. The demographic and biomedical case for late-life interventions in aging. Sci. Transl. Med. 2010, 2. 40cm21.
28. Rey F.E., Pagano P.J. The reactive adventitia: fibroblast oxidase in vascular function. Arterioscler. Thromb. Vasc. Biol. 2002, 1962-1971.
29. Sachse A., Wolf G.J. Angiotensin II-induced reactive oxygen species and the kidney. Am. Soc. Nephrol. 2007, 2439-2446.
30. Saleh S., Ain-Shoka A.A., El-Demerdash E., Khalef M.M. Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy 2009, 399-406.
31. Santos E., de Picoli Souza K., da Silva E., Batista E., Martins P., D'Almeida V., Pesquero J. Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. Biochem. Pharmacol. 2009, 78(8):951-958.
32. Sugimoto K., Tsuruoka S., Fujimura A. Effect of enalapril on diabetic nephropathy in OLETF rats: the role of an anti-oxidative action in its protective properties. Clin. Exp. Pharmacol. Physiol. 2001, 28:826-830.
33. Sung B., Park S.J., Yu B.Y., Chung H.Y. Modulation of PPAR in aging, inflammation, and calorie restriction. J. Gerontol. A Biol. Sci. Med. Sci. 2004, 59:997-1006.
34. Thompson M.M., Oyama T.T., Kelly F.J., Kennefick T.M., Anderson S. Activity and responsiveness of the renin-angiotensin system in the aging rat. Am. J. Physiol. 2000, R1787-R1794.
35. Vaziri N.D., Bai Y., Ni Z., Quiroz Y., Pandian R., Rodriguez-Iturbe B. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J. Pharmacol. Exp. Ther. 2007, 85-93.
36. Viatour P., Merville M., Bours V., Chariot A. Phosphorylation of NF-[kappa] B and I [kappa] B proteins: implications in cancer and inflammation. Trends Biochem. Sci. 2005, 30:43-52.
37. Wei Y., Sowers J.R., Clark S.E., Li W., Ferrario C.M., Stump C.S. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am. J. Physiol. Endocrinol. Metab. 2008, E345-E351.
38. Yamazaki T., Tanimoto M., Gohda T., Ohara I., Hagiwara S., Murakoshi M., Matsumoto M., Kaneko S., Aoki T., Toyoda H., Ishikawa Y., Funabiki K., Horikoshi S., Tomino Y. Combination effects of enalapril and losartan on lipid peroxidation in the kidneys of KK-Ay/Ta mice. Nephron Exp. Nephrol. 2009, 113:e66-e76.
39. Zafari A.M., Ushio-Fukai M., Akers M., Yin Q., Shah A., Harrison D.G., Taylor D.R., Griendling K.K. Novel role of NADH/NADPH oxidase-derived hydrogen peroxide in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 1998, 488-495.
40. Zhong H., May M., Jimi E., Ghosh S. The phosphorylation status of nuclear NF-[kappa] B determines its association with CBP/p300 or HDAC-1. Mol. Cell 2002, 9:625-636.